Ernst R. Berndt

Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness (2007)

Berndt, Ernst R., Glennerster, Rachel, Kremer, Michael R., Lee, Jean, Levine, Ruth, Weizsacker, Georg, ...

The G8 is considering committing to purchase vaccines against diseases concentrated in low-income countries (if and when desirable vaccines are developed) as a way to spur research and development on...

Real Output in Mental Health Care during the 1990s (2006)

Berndt, Ernst R., Busch, Alisa B., Frank, Richard G., Normand, Sharon-Lise

Health accounts document changes over time in the level and composition of health spending. There has been a continued evolution in the ability to track such outlays. Less rapid has been the ability...

Advanced purchase commitments for a malaria vaccine: estimating costs and effectiveness (2005)

Berndt, Ernst R., Glennerster, Rachel, Kremer, Michael R., Lee, Jean, Levine, Ruth, Weizsacker, Georg, ...

To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when...

Advanced purchase commitments for a malaria vaccine: estimating costs and effectiveness (2005)

Berndt, Ernst R., Glennerster, Rachel, Kremer, Michael R., Lee, Jean, Levine, Ruth, Weizsäcker, Georg, ...

To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when...

Testing for the Existence of a Consistent Aggregate Index of Labor Inputs, (2005)

Berndt,Ernst R., Christensen,Laurits R.

The purpose of the report is to estimate a production function for U. S. manufacturing with the labor input disaggregated into production and nonproduction workers, and then to test whether a...

The Internal Structure of Functional Relationships: Separability, Substitution, and Aggregation, (1998)

Berndt,Ernst R., Christensen,Laurits R.

The purpose of the report is to integrate the discussions on functional separability and substitution properties. In the context of production theory, the authors state and prove theorems which...

The Translog Production Function and Factor Substitution in U.S. Manufacturing 1929-1968, (1998)

Berndt,Ernst R., Christensen,Laurits R.

The paper contains an empirical application of the translog production function proposed by Christensen, Jorgenson, and Lau. The application is a study of substitution possibilities among equipment,...

Productivity measurement using capital asset valuation to adjust for variations in utilization (1981)

Berndt, Ernst R., Fuss, Melvyn A.

Also released as Working Paper No. 8125, Institute for Policy Analysis, University of Toronto. *An earlier version was presented at the econometric Society Summer Meetings, San Diego, California,...

Productivity measurement using capital asset valuation to adjust for variations in utilization (1981)

Berndt, Ernst R., Fuss, Melvyn A.

Also released as Working Paper No. 8125, Institute for Policy Analysis, University of Toronto. *An earlier version was presented at the econometric Society Summer Meetings, San Diego, California,...

The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke and Myocardial Infarction in the United States

Genia Long, David Cutler, Ernst R. Berndt, Jimmy Royer, Andrée-Anne Fournier, Alicia Sasser, ...

Estimating the value of medical innovation is a continual challenge. In this research, we quantify the impact of antihypertensive therapy on U.S. blood pressures, risk and number of heart attacks,...

Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness

Ernst R. Berndt, Rachel Glennerster, Michael R. Kremer, Jean Lee, Ruth Levine, Georg Weizsacker, ...

To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when...

Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process

Ernst R. Berndt, Tomas Philipson, Matthew W. Strobeck

Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within...

Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts

Tomas J. Philipson, Ernst R. Berndt, Matthew W. Strobeck

The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies,...

Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA

Ernst R. Berndt, Matthew W. Strobeck

In the United States, the Food and Drug Administration (FDA) agency is responsible for regulating the safety and efficacy of biopharmaceutical drug products. Furthermore, the FDA is tasked with...

The Boskin Commission Report After a Decade: After-life or Requiem?

Ernst R. Berndt

The author provides a political economy interpretation of the rise and fall of public interest in price measurement, placing these developments in the context of the attempt by Congress and the White...

Early Retirement and Public Disability Insurance Applications: Exploring the Impact of Depression

Rena M. Conti, Ernst R. Berndt, Richard G. Frank

This paper investigates the impact of depression on labor force participation among older workers. Empirically, we use two analytic strategies and rely on a sample drawn from the Health and...

Medical care prices and output

Berndt, Ernst R., Cutler, David M., Frank, Richard G., Griliches, Zvi, Newhouse, Joseph P., Triplett, Jack E., ...

We review in considerable detail the conceptual and measurement issues that underlie construction of medical care price indexes in the US, focusing in particular on the medical care consumer price...

Advance Market Commitments for Vaccines Working Paper and Spread Sheet

Ruth Levine, Ernst R. Berndt, Rachel Glennerster, Michael R. Kremer, Jean Lee, Georg Weizsacker, ...

The G8 is considering committing to purchase vaccines against diseases concentrated in low-income countries (if and when desirable vaccines are developed) as a way to spur research and development on...

Economic Capacity Utilization and Productivity Measurement for Multi- product firms with multiple quasi-fixed inputs

Ernst R. Berndt, Melvyn A. Fuss

In this paper we develop measures of economic capacity output and economic capacity utilization for firms producing multiple outputs and having one or .ore quasi-fixed inputs. Although we produce an...

Auditing the Producer Price Index: Micro Evidence From Prescription Pharmaceutical Preparations

Ernst R. Berndt, Zvi Griliches, Joshua G. Rosett

In this paper we focus on a mystery we uncovered while undertaking a detailed audit of the US Bureau of Labor Statistics producer price index (PPl). We summarize our puzzle as follows. From January...

High-Tech Capital Formation and Labor Composition in U.S. Manufacturing Industries: An Exploratory Analysis

Ernst R. Berndt, Catherine J. Morrison, Larry S. Rosenblum

In this paper we report results of an exploratory empirical effort examining relationships between investments in high-tech information technology capital and the distribution of employment, both by...

Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness

Ernst R. Berndt, Rachel Glennerster, Michael R. Kremer, Jean Lee, Ruth Levine, Georg Weizsäcker

To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when...

Productivity Measurement Using Capital Asset Valuation to Adjust for Variations in Utilization

Ernst R. Berndt, Melvyn A. Fuss

Although a great deal of empirical research on productivity measurement has taken place in the last decade, one issue remaining particularly controversial and decisive is the manner by which one...

Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion

Ernst R. Berndt, Patricia M. Danzon, Gregory B. Kruse

We report on an exploratory examination of the extent of differences across fifteen countries and three therapeutic classes (antihypertensives, antidepressants and antiepileptics) in the rate at...

A primer on the economics of re-importation of prescription drugs

Ernst R. Berndt

Using the basic tools of intermediate microeconomic theory (such as taught at the level of undergraduate or first-year MBA courses), in this primer I present a framework that helps the reader gain an...

Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion

Ernst R. Berndt, Patricia M. Danzon, Gregory B. Kruse

We report on an exploratory examination of the extent of differences across fifteen countries and three therapeutic classes (antihypertensives, antidepressants and antiepileptics) in the rate at...

A primer on the economics of re-importation of prescription drugs

Ernst R. Berndt

Using the basic tools of intermediate microeconomic theory (such as taught at the level of undergraduate or first-year MBA courses), in this primer I present a framework that helps the reader gain an...

Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price

Ernst R. Berndt

The U.S. pharmaceutical industry has again become the focus of considerable controversy. In understanding the economics underlying this industry, distinctions between short, medium and long-run costs...

Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs

Ernst R. Berndt, Robert S. Pindyck, Pierre Azoulay

We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a therapeutic class of drugs. Externalities emerge when use of a drug by others...

Measuring the Contribution of Public Infrastructure Capital in Sweden.

Berndt, Ernst R, Hansson, Bengt

The authors purpose is to examine ways of evaluating and measuring the contribution of public infrastructure capital to private sector output and productivity growth in Sweden. They do this by...

ECONOMIC INCENTIVES AND CONTRACTS: THE USE OF PSYCHOTROPIC MEDICATIONS

DAVINA C. LING, ERNST R. BERNDT, RICHARD G. FRANK

"The advent of novel psychotropic medications has revolutionized treatments for mental illnesses over the past few decades. Concurrently, changes in mental health coverage, particularly for Medicaid...

Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness

Ernst R. Berndt, Rachel Glennerster, Michael R. Kremer, Jean Lee, Ruth Levine, Georg Weizsäcker, ...

The G8 is considering committing to purchase vaccines against diseases concentrated in low-income countries (if and when desirable vaccines are developed) as a way to spur research and development on...

Auditing the Producer Price Index: Micro Evidence from Prescription Pharamceutical Preparations.

Berndt, Ernst R, Griliches, Zvi, Rosett, Joshua G

From January 1984 through December 1989, the Bureau of Labor Statistics (BLS) price index for prescription pharmaceuticals grew at 9.09 percent per year. Using BLS-type Laspeyres index procedures...

Energy price changes and the induced revaluation of durable capital in U.S. manufacturing

Berndt, Ernst R., Wood, David O.

HD28 .M414 no.1455-, 83, Manufactures Economic aspects, Power resources Prices,

Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia

Pierre-Yves Cremieux, Stan N. Finkelstein, Ernst R. Berndt, Jeffrey Crawford, Mitchell B. Slavin

Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for...

Generic Entry, Reformulations and Promotion of SSRIs in the US

Haiden A. Huskamp, Julie M. Donohue, Catherine Koss, Ernst R. Berndt, Richard G. Frank

Background: Previous research has shown that a manufacturer's promotional strategy for a brand name drug is typically affected by generic entry. However, little is known about how newer strategies to...